Participants age 30-60 years, have mild to moderate severity of infraorbital hallow and eye ptosis periorbital, micro-focused ultrasound, hyaluronic acid fillers, botox
Conditions
Interventions
Combination therapies from a single manufacturer (Merz Pharma, GmbH): micro-focused ultrasound with visualization (MFU-V
Ultherapy), hyaluronic acid fillers (HA
Belotero range, including Balance [BB], and Soft [BS]) and incobotulinumtoxinA (BoNT-A
Xeomin).
Experimental Device
Combination therapies
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. participants with mild to moderate severity of infraorbital hallow and eye ptosis 2. willing to participate in the study
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women 2. Treated with botulinum toxin, filler, micro-focused ultrasound, or laser treatment in the past 12 months 3. Having coagulation disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infraorbital volume improvement Baseline, 2 weeks, 12 weeks, 14 weeks, 16 weeks, 24 weeks Vectra H1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Eyebrow lifting Baseline, 2 weeks, 12 weeks, 14 weeks, 16 weeks, 24 weeks ImageJ,Physician and patient assessment Baseline, 2 weeks, 12 weeks, 14 weeks, 16 weeks, 24 weeks percent improvement,Safety Baseline, 2 weeks, 12 weeks, 14 weeks, 16 weeks Side effects | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed